Monthly Archives: May 2011

Pernix Therapeutics Holdings Reports First Quarter 2011 Financial Results

Net Revenues Increased 14% to $10.1 Million in the First Quarter 2011 EBITDA of $2.2 Million in the First Quarter 2011 Launched Cedax® (ceftibuten), 180 mg oral suspension in January 2011 MAGNOLIA, Texas, May 17, 2011 – Pernix Therapeutics Holdings, Inc. (“Pernix”) (NYSE Amex: PTX), a specialty pharmaceutical company primarily...
Read more